Share:
During the past month we have seen increased interest in our virus research reagents portfolio. This has doubtless been prompted by biotech companies responding to the COVID-19 crisis.
Although the reagents that Cambridge Enterprise has available do not relate directly to COVID-19, they are extremely helpful for advancing general virus research. They are well-established reagents, which have been researched and used in academic and commercial labs for years. Researchers can utilise them as a starting point for designing new detection kits and other relevant assays. Progression in this area could ultimately help to inform and speed up the research and development process around COVID-19.
Cambridge Enterprise has a range of virus reagents available to license non-exclusively, under standard terms and conditions. They fall into three main categories:
- Murid Herpesvirus-4 (MuHV 4) antibodies
- Herpes Simplex Virus Type 1 and 2 (HSV-1 and -2) antibodies
- W-12 cell lines
To find out more, please download the marketing sheet and contact the Reagents Administrator.
Cambridge Enterprise also offers access to a wide range of other research reagents that are also available for commercial licensing. Please visit our available reagents page to find out more.
